PMID- 38301089
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240214
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Print)
IS  - 1029-2977 (Linking)
VI  - 26
IP  - 5
DP  - 2023 May 1
TI  - Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A 
      Case-Control Study in the Iranian Population.
PG  - 261-266
LID - 10.34172/aim.2023.40 [doi]
AB  - BACKGROUND: As an emerging pandemic disease, COVID-19 encompasses a spectrum of 
      clinical diagnoses, from the common cold to severe respiratory syndrome. 
      Considering the shreds of evidence demonstrating the relationship between human 
      leukocyte antigen (HLA) allele diversity and infectious disease susceptibility, 
      this study was conducted to determine the association of HLA alleles with 
      COVID-19 severity in Iranian subjects. METHODS: In this case-control study, a 
      total of 200 unrelated individuals (consisting of 100 people with severe COVID-19 
      and an average age of 55.54 as the case group, and 100 patients with mild 
      COVID-19 with an average age of 48.97 as the control group) were recruited, and 
      HLA typing (Locus A, B, and DR) was performed using the Olerup sequence-specific 
      oligonucleotide (SSO) HLA-typing kit. RESULTS: Our results showed that HLA-A*11 
      and HLA-DRB1*14 alleles were more frequently observed in severe COVID-19 cases, 
      while HLA-B*52 was more common in mild cases, which was in agreement with some 
      previous studies. CONCLUSION: Our results confirmed the evidence for the 
      association of HLA alleles with COVID-19 outcomes. We found that HLA-A*11 and 
      HLA-DRB1*14 alleles may be susceptibility factors for severe COVID-19, while 
      HLA-B*52 may be a protective factor. These findings provide new insight into the 
      pathogenesis of COVID-19 and help patient management.
CI  - (c) 2023 The Author(s). This is an open-access article distributed under the terms 
      of the Creative Commons Attribution License 
      (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, 
      distribution, and reproduction in any medium, provided the original work is 
      properly cited.
FAU - Mashayekhi, Parisa
AU  - Mashayekhi P
AUID- ORCID: 0000-0002-6373-3266
AD  - Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute 
      of Iran, Tehran, Iran.
FAU - Omrani, Mir Davood
AU  - Omrani MD
AUID- ORCID: 0000-0002-0673-9717
AD  - Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Yassin, Zeynab
AU  - Yassin Z
AUID- ORCID: 0000-0002-1915-6596
AD  - Antimicrobial resistance Research Center, Institute Of Immunology And Infectious 
      Disease, Iran University of Medical Sciences, Tehran, Iran.
FAU - Dehghanifard, Ali
AU  - Dehghanifard A
AD  - Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute 
      of Iran, Tehran, Iran.
FAU - Ashouri, Leila
AU  - Ashouri L
AD  - Antimicrobial resistance Research Center, Institute Of Immunology And Infectious 
      Disease, Iran University of Medical Sciences, Tehran, Iran.
FAU - Aghabozorg Afjeh, Sara Sadat
AU  - Aghabozorg Afjeh SS
AUID- ORCID: 0000-0002-6352-9310
AD  - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Shabanzadeh, Zahra
AU  - Shabanzadeh Z
AD  - Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute 
      of Iran, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230501
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - HLA-DRB1 Chains/genetics
MH  - Iran/epidemiology
MH  - Gene Frequency
MH  - Case-Control Studies
MH  - *Genetic Predisposition to Disease
MH  - *COVID-19/genetics
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/genetics
MH  - Alleles
MH  - Haplotypes
PMC - PMC10685865
OTO - NOTNLM
OT  - COVID-19
OT  - HLA
OT  - Susceptibility
COIS- Competing Interests The authors declare no conflict of interest.
EDAT- 2024/02/01 18:42
MHDA- 2024/02/05 06:44
PMCR- 2023/05/01
CRDT- 2024/02/01 14:46
PHST- 2022/11/05 00:00 [received]
PHST- 2023/03/12 00:00 [accepted]
PHST- 2024/02/05 06:44 [medline]
PHST- 2024/02/01 18:42 [pubmed]
PHST- 2024/02/01 14:46 [entrez]
PHST- 2023/05/01 00:00 [pmc-release]
AID - 10.34172/aim.2023.40 [doi]
PST - epublish
SO  - Arch Iran Med. 2023 May 1;26(5):261-266. doi: 10.34172/aim.2023.40.